Dipiperazine‐Phenyl Derivatives Based on Convergent Molecular Platforms Can Reverse Multidrug Resistance in Gram‐Negative Bacteria by Inhibiting Efflux and Permeabilizing Cell Membranes
Advanced Science · 2026
DOI: 10.1002/advs.202512859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Jiale Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, School of Pharmaceutical S…. Hauptthemen laut MEDLINE: Drug Resistance, Multiple, Bacterial, Gram-Negative Bacteria, Anti-Bacterial Agents, Piperazines. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
With the global surge of infections caused by multidrug‐resistant (MDR) Gram‐negative bacteria, there is an urgent need for breakthrough therapeutic approaches. To overcome the intrinsic resistance mechanisms of bacteria, End‐alkyl‐modified dipiperazine‐phenyl derivatives are designed via convergent molecular platforms (CMPs)‐guided multi‐target directed ligand (MTDL) strategy. These dual‐functional compounds not only inhibit the AcrB‐TolC efflux pump system but also enhance bacterial membrane permeability and display a distinctive activity profile across a broad concentration range. Through integrated evaluation combining in vitro activity screening and computational ADMET (absorption, distribution, metabolism, excretion, toxicity) profiling, compound C5 is identified as a promising lead candidate. This compound achieved three notable breakthroughs. First, it reduces biofilm formation by 80% at 1/64 minimum inhibitory concentration (MIC) when combined with antibiotics. Second, unlike conventional antibiotic adjuvants that typically display potentiation within a narrow concentration window (1/4 MIC), C5 maintained robust and consistent synergistic activity across a broad range from 1/64 MIC to 1/4 MIC. Third, C5 markedly enhanced the therapeutic efficacy of antibiotics such as minocycline by over 1000‐fold in in vivo infection models, without causing detectable acute toxicity or cytotoxicity. The established MTDL‐CMPs integrated platform pioneers a novel “pump‐membrane dual blockade” therapeutic paradigm against MDR Enterobacteriaceae infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shan…
ORCID-Profile: Jiale Dong, Shutao Ma
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Dong, J., Guo, T., Huang, Y., Ma, Y., Chen, W., Xue, J., Jiang, J., Dong, E., Kong, Y., Ding, H., Zhang, W., & Ma, S. (2026). Dipiperazine‐Phenyl Derivatives Based on Convergent Molecular Platforms Can Reverse Multidrug Resistance in Gram‐Negative Bacteria by Inhibiting Efflux and Permeabilizing Cell Membranes. Advanced Science. https://doi.org/10.1002/advs.202512859
Vancouver
Dong J, Guo T, Huang Y, Ma Y, Chen W, Xue J, et al. Dipiperazine‐Phenyl Derivatives Based on Convergent Molecular Platforms Can Reverse Multidrug Resistance in Gram‐Negative Bacteria by Inhibiting Efflux and Permeabilizing Cell Membranes. Advanced Science. 2026. doi:10.1002/advs.202512859
BibTeX
@article{Dong2026,
author = {Dong, Jiale and Guo, Ting and Huang, Yi and Ma, Yangchun and Chen, Weijin and Xue, Jie and Jiang, Jun and Dong, Enhui and Kong, Yue and Ding, Hang and Zhang, Wenlong and Ma, Shutao},
title = {Dipiperazine‐Phenyl Derivatives Based on Convergent Molecular Platforms Can Reverse Multidrug Resistance in Gram‐Negative Bacteria by Inhibiting Efflux and Permeabilizing Cell Membranes},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202512859}
}
EUVIMED